SELLAS Life Sciences (SLS) Profit After Tax (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Profit After Tax data on file, last reported at -$8.4 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 44.5% year-over-year to -$8.4 million in Q1 2026; TTM through Mar 2026 was -$29.5 million, a 8.7% decrease from a year earlier, with the FY2025 full-year figure at -$26.9 million, up 12.89% from the prior year.
• Profit After Tax for Q1 2026 stood at -$8.4 million, down from -$7.7 million in the prior quarter.
• Over the last five years, Profit After Tax for SLS reached as high as -$5.8 million in Q1 2025 and fell as low as -$16.7 million in Q1 2022.
• Historically, Profit After Tax has averaged -$8.5 million across 5 years, with a median of -$8.1 million in 2023.
• Across the five-year window, Profit After Tax slumped 596.8% in 2022 and soared 39.23% in 2025, its largest moves.
• Year by year, Profit After Tax stood at -$9.1 million in 2022, then gained by 10.8% to -$8.1 million in 2023, then gained by 17.2% to -$6.7 million in 2024, then decreased by 14.22% to -$7.7 million in 2025, then retreated by 9.16% to -$8.4 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$8.4 million in Q1 2026, -$7.7 million in Q4 2025, and -$6.8 million in Q3 2025.